ArticleTranslational lung cancer research2026
Association of FDG PET/CT and immune profiling with pathologic complete response after neoadjuvant immunotherapy in stage II-III non-small cell lung cancer.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant immunotherapy has emerged as a transformative approach for resectable non-small cell lung cancer (NSCLC). Pathologic complete response (pCR) after neoadjuvant therapy serves as a robust surrogate marker for early treatment efficacy and long-term outcomes. However, reliable noninvasive predictors of pCR before surgery remain an unmet clinical need. This study investigated the association between fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) parameters and tumor-infiltrating immune cell subsets in pre-treatment biopsies with pCR in patients with stage II-III NSCLC treated with immune checkpoint inhibitor (ICI)-based neoadjuvant therapy. Methods: We retrospectively analyzed 13 patients with stage II-III NSCLC who underwent ICI-based neoadjuvant therapy and baseline FDG PET/CT. pCR was assessed in resected surgical specimens. PET/CT parameters, including tumor-to-liver ratio (TLR) and maximum standardized uptake value (SUVmax), were evaluated before and after neoadjuvant treatment. Multiplex immunofluorescence (mIF) was performed on pre-treatment tumor biopsies to quantify tumor-infiltrating immune cell subsets and functional immune markers. Results: Eight patients (62%) achieved pCR. Compared with the non-pCR group, patients with pCR showed significantly lower post-treatment TLR (median 1.51 Conclusions: Dynamic changes in PET/CT-derived TLR and immune biomarkers from pre-treatment biopsies were associated with pCR following neoadjuvant immunotherapy in stage II-III NSCLC. These findings support the complementary role of metabolic imaging and immune profiling in improving patient selection and perioperative decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.